Worldwide facing Alzheimer's drug discovery bottlenecks
Sting of Alzheimer’s failures offset by upcoming prevention trials
Nature Reviews Drug Discovery 11:657, 2012
Three prevention trials in asymptomatic Alzheimer’s disease patients
will
attempt to validate the amyloid
hypothesis, evaluate biomarkers and set
the
stage for drug approvals.
Alzheimer’s
disease, Dementia, is commonly
known as Senile dementia. Early phase of Alzheimer’s also known as mild cognitive impairment. Its early symptoms of learning and memory
impairment allow physicians to diagnose the disease. As the disease progresses to mid-term, patients will lose independence and
become unable to carry out daily activities. During the final stage of Alzheimer's disease, the patient is completely
dependent on caregivers. According to many surveys,
15% of people over the age of 80 are suffering from dementia. Once we begin to
consciously take notice of our forgetfulness, the inevitable effects of aging have
already begun, and healthy
longevity with optimal mental function should be our ultimate goal.
As of 2012, more than
1000 clinical trials have been performed studying how to treat Alzheimer’s, however, it is
still unknown whether this research found any method of treatment that are
truly effective. Even prominent persons such as former United
States President Ronald Reagan and the former United Kingdom's Prime Minister
Margaret Thatcher, both of whom had access to the best medical care, were still
unable to escape death from Alzheimer's. Therefore, the existing medication has shown limited
effectiveness in the long term.
In Western medicine, drug development usually focuses on inhibition rationale, for example, anti-cancer drugs are designed to
inhibit the growth of cancer cells, but whether these drugs will kill the
faster growing bone marrow stem cells really depend on fortune of the patients.
Alzheimer’s drug development is no exception. Currently, the
two clinical treatments are acetylcholine enzyme inhibitors or NMDA receptor inhibitors. Acetylcholine enzyme inhibitors
focus on inhibition of the enzyme acetylcholinesterase
which breaks down acetylcholine, a neurotransmitter required for memory
function. NMDA receptor inhibitors were developed to address an excess of the
nerve conduction factor glutamate which binds the NMDA
receptors on brain cells. NMDA receptors are the predominant molecular device
for controlling synaptic plasticity and memory function. The suppression
philosophy of new drug development for
the last 60 years has not proven satisfactory, and yet this philosophy continues. This has created a bottleneck in Western drug
development. The failure of the last two inhibitory monoclonal antibody drugs in clinical phase III left these big
international pharmaceutical companies, Pfizer, Johnson & Johnson (J&J) and Elan, not knowing how
to proceed further. In an attempt to move beyond these disappointing results,
researchers both inside these pharmaceutical companies and in independent
laboratories have now turned to development of preventive drug rather than therapeutic drugs for Alzheimer’s
disease. They barely
hope that treating patients with no symptoms or early onset symptoms might give
them better chance for success in Alzheimer’s drug development.
The AcaMed
company’s R&D team used
the electronic database containing 700 kinds of ancient traditional Chinese medicine books and found
that reishi is one of
the few herbs that were recorded to have the effect on enhancing intelligence. After many years of research , we found that the extract and the purified compounds from reishi can induce
glial cells for nerve growth factor production, and this
nerve growth factor has the ability to remove the accumulation of
abnormal aggregates of the neuronal cells,
thus allowing our neurons to
resume long-term memory function. Our company’s R&D team has published this study in the world famous journal “Neuropharmacology (2012)”. In addition, we
discovered that shouwu and huangjing concentrates
will induce neurons to produce
erythropoietin and to promote energy generation of mitochondria. Further studies showed considerable improvement in experimental
animal models of Alzheimer's disease and neuronal injury.
“SmarT-101” is produced based on the traditional Oriental medicine approach
of promoting cellular and body functions. Just like a computer hard drive will slow down after a period of usage and needed to defrag and
re-organize the hard disk space, our brains need to restore themselves during sleep. “SmarT-101”can help us clear the accumulation of waste in our brain during our sleep. “SmarT-101” can improve the
quality of your sleep and thus upgrade the overall quality of your daily life. We also believe
this product will be gradually accepted by consumers. Wishing all of you
health and happiness!!!
http://www.acamed.com.tw/